|
Synonyms: 7E3 antibody | antiGPIIBIIIa | C7E3 | ReoPro®
abciximab is an approved drug (FDA (1994))
Compound class:
Antibody
Comment: Abciximab is a chimeric human-murine monoclonal antibody Fab (fragment antigen binding) fragment designed to target glycoprotein IIb/IIIa receptor, a key mediator of platelet aggregation and clot formation [2]. The invention of abciximab is covered by patent US5976532 [1], where its originating antibody is coded c7E3.
View more information in the IUPHAR Pharmacology Education Project: abciximab |
| No information available. |
Summary of Clinical Use  |
| Used in the management of cardiac ischemia. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Abciximab is an antagonist of the integrin, glycoprotein IIb/IIIa receptor (CD41, aka integrin αIIbβ3). Abciximab prevents fibrinogen-mediated activation of αIIbβ3 on platelets and this action reduces platelet aggregation and clot formation. |
| External links |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com |
